United Therapeutics (UTHR) Accounts Payables (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Accounts Payables data on file, last reported at $498.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 35.78% year-over-year to $498.3 million; the trailing twelve-month figure through Mar 2026 stood at $498.3 million (up 35.78% YoY), and the FY2025 full-year result was $488.0 million, up 41.65% from the prior year.
• Accounts Payables improved to $498.3 million in Q1 2026, from $488.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $498.3 million in Q1 2026 to a low of $166.4 million in Q1 2022.
• A 5-year average of $327.5 million and a median of $325.3 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables gained 0.85% in 2022 and soared 51.48% in 2023, its largest moves.
• Tracing UTHR's Accounts Payables over 5 years: stood at $229.9 million in 2022, then gained by 29.62% to $298.0 million in 2023, then advanced by 15.6% to $344.5 million in 2024, then soared by 41.65% to $488.0 million in 2025, then rose by 2.11% to $498.3 million in 2026.
• Business Quant data shows UTHR's Accounts Payables at $498.3 million in Q1 2026, $488.0 million in Q4 2025, and $468.0 million in Q3 2025.